--- title: "Akebia Therapeutics (AKBA) news: reverse split and offering" url: "https://aibio.space/companies/akebia-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AKBA reverse split and offering news: Akebia Therapeutics gets Nasdaq bid price notice, has until April 19, 2027. Akebia Therapeutics, Inc." --- AKBA Akebia Therapeutics, Inc. NASDAQ · United States # Akebia Therapeutics (AKBA) news AKBA reverse split and offering news Listings · 2026-10-23 ## [Akebia Therapeutics gets Nasdaq bid price notice, has until April 19, 2027](https://aibio.space/news/akebia-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-19/) Nasdaq says the stock closed below $1.00 for 30 consecutive business days. Cash fell from $184.8 million at year-end 2025 to $155.5 million at June 30, 2026, and the company says it could seek a reverse stock split. ## Latest Akebia Therapeutics news 1. 2026-06-22 Listings [Akebia stockholders approve raising authorized common shares to 500,000,000](https://aibio.space/news/akebia-stockholders-approve-raising-authorized-common-shares-500-000/) Stockholders approved raising authorized common stock from 350,000,000 to 500,000,000 at a June 17, 2026 meeting, with 88,853,129 votes against. The 8-K does not say how many shares are outstanding or planned for issue. 2. 2025-12-01 Mergers [Q32 Bio sells ADX-097 to Akebia Therapeutics for $7.0 million upfront](https://aibio.space/news/q32-bio-sells-adx-097-akebia-therapeutics-7-0-million-upfront/) Q32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027. 3. 2025-03-19 Financings [Akebia launches stock offering, then prices 25,000,000 shares at $2.00 for $50.0 million](https://aibio.space/news/akebia-launches-stock-offering-then-prices-25-000-000-shares-2-00-50-0/) Akebia priced 25,000,000 shares at $2.00 for gross proceeds of $50.0 million, below the $2.84 last sale price the final prospectus cites for March 19, 2025. The company estimates net proceeds of about $46.5 million and reports an accumulated deficit of $1,678,360 thousand. 4. 2025-02-07 Debt Financing [Akebia Therapeutics draws $10.0 million Tranche C loan from Kreos, receives $9.3 million net](https://aibio.space/news/akebia-therapeutics-draws-10-0-million-tranche-c-loan-kreos-receives-9/) Akebia drew the extended $10.0 million Tranche C loan on February 3, 2025, the last day of its extension. It received $9.3 million net and issued a warrant to a Kreos affiliate for 1,153,846 shares at $1.30 a share. 5. 2025-02-07 Debt Financing [Akebia extends Kreos loan tranche, draws $10.0 million and issues 1,153,846-share warrant](https://aibio.space/news/akebia-extends-kreos-loan-tranche-draws-10-0-million-issues-1-153-846/) Akebia received net proceeds of $9.3 million on February 3, 2025. The warrant has an exercise price of $1.30 per share and runs eight years. ## Akebia Therapeutics at a glance - **Ticker**: AKBA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $155.5 million ### Related companies - [Rezolute](https://aibio.space/companies/rezolute/) NASDAQ: RZLT - [Anebulo Pharmaceuticals](https://aibio.space/companies/anebulo-pharmaceuticals/) OTC: ANEB - [Outlook Therapeutics](https://aibio.space/companies/outlook-therapeutics/) NASDAQ: OTLK - [Werewolf Therapeutics](https://aibio.space/companies/werewolf-therapeutics/) NASDAQ: HOWL - [Accustem Sciences](https://aibio.space/companies/accustem-sciences/) OTC: ACUT - [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) NASDAQ: AMLX - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) NASDAQ: TENX - [Emergent BioSolutions](https://aibio.space/companies/emergent-biosolutions/) NYSE: EBS ### Also on NASDAQ - [XBiotech](https://aibio.space/companies/xbiotech/) XBIT - [Celcuity](https://aibio.space/companies/celcuity/) CELC - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) RLAY - [CorMedix](https://aibio.space/companies/cormedix/) CRMD - [Apyx Medical](https://aibio.space/companies/apyx-medical/) APYX - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) ORGO ## What Akebia Therapeutics does Akebia Therapeutics is a fully integrated biopharmaceutical company with two commercial products for patients with kidney disease. Its pipeline includes mid-stage programs for rare kidney diseases and early-stage programs for kidney disease and non-kidney indications. Its oral product Vafseo (vadadustat) was approved by the FDA in March 2024 for anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months, and it entered the U.S. market in January 2025. Auryxia (ferric citrate) is approved and marketed in the U.S. for serum phosphorus control in dialysis-dependent CKD and for iron deficiency anemia in non-dialysis-dependent CKD. The text says Auryxia reached loss of exclusivity in March 2025, and that Teva received tentative approval for its Abbreviated New Drug Application for Auryxia in January 2026. Mid-stage rare kidney disease assets include praliciguat, an oral soluble guanylate cyclase stimulator being evaluated in a Phase 2 trial for focal segmental glomerulosclerosis (FSGS), and AKB-097, a complement inhibitor acquired from Q32 Bio in November 2025. Early-stage assets include AKB-9090 and AKB-10108, which the text describes as HIF molecules. The text says CKD potentially affects approximately 35.5 million patients in the United States. | Product or program | What it is | Stage | |---|---|---| | Vafseo | Oral treatment for anemia due to CKD in adults on dialysis | approved | | Auryxia | Oral ferric citrate for phosphorus control and iron deficiency anemia in CKD | approved and marketed in the U.S. | | praliciguat | Oral soluble guanylate cyclase stimulator for FSGS | Phase 2 | | AKB-097 | Anti-C3d-Factor H fusion protein complement inhibitor for rare kidney diseases | clinical-stage | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm). ## Akebia Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$62.4 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/) | [$37.7 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/) | | Net income (loss) | [-$5.3 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/) | [-$69.4 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/) | | Cash from operations | [$68.0 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/) | [-$40.7 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/) | | Cash and equivalents | [$184.8 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/) | [$51.9 million](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $155.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Akebia Therapeutics Did Akebia Therapeutics do a reverse stock split? Our latest story on this, dated Oct 23, 2026: "Akebia Therapeutics gets Nasdaq bid price notice, has until April 19, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/akebia-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-19/). Has Akebia Therapeutics raised money recently? Our latest story on this, dated Mar 19, 2025: "Akebia launches stock offering, then prices 25,000,000 shares at $2.00 for $50.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/akebia-launches-stock-offering-then-prices-25-000-000-shares-2-00-50-0/). What is the ticker symbol of Akebia Therapeutics? Akebia Therapeutics, Inc. trades under the ticker AKBA on NASDAQ. Where is Akebia Therapeutics listed? Akebia Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:AX9; LS:A1XF0S; LSX:A1XF0S. What is the SEC CIK of Akebia Therapeutics? The SEC Central Index Key (CIK) for Akebia Therapeutics, Inc. is 1517022. Its filings are on SEC EDGAR. How many shares does Akebia Therapeutics have outstanding? 277,106,245 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Akebia Therapeutics listed under? Our directory records Akebia Therapeutics, Inc. under United States. What does Akebia Therapeutics do? Our directory classifies Akebia Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Akebia Therapeutics? The ISIN recorded for Akebia Therapeutics, Inc. is US00972D1054. Does aibio.space cover Akebia Therapeutics? aibio.space lists Akebia Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Akebia Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Akebia Therapeutics develop? Akebia Therapeutics is a fully integrated biopharmaceutical company with two commercial products for patients with kidney disease. Its pipeline includes mid-stage programs for rare kidney diseases and early-stage programs for kidney disease and non-kidney indications. What is Vafseo from Akebia Therapeutics? Vafseo: Oral treatment for anemia due to CKD in adults on dialysis Stage: approved. What is Auryxia from Akebia Therapeutics? Auryxia: Oral ferric citrate for phosphorus control and iron deficiency anemia in CKD Stage: approved and marketed in the U.S.. Is Akebia Therapeutics profitable? Akebia Therapeutics, Inc. reported a net loss of $5.3 million for the fiscal year ended Dec 31, 2025, and generated $68.0 million of cash from operations, per its annual report to the SEC. ## Investor discussion: Akebia Therapeutics Members talk about Akebia Therapeutics (AKBA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Akebia Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000075/akba-20261021.htm) 2. 2026-06-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/akba-20260617.htm) 3. 2025-03-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1517022/000119312525057843/d892132d424b5.htm) 4. 2025-02-07 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000010/akba-20250203.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AKBA on TradingView](https://www.tradingview.com/symbols/NASDAQ-AKBA/). ## SEC filings and registration - **SEC name**: Akebia Therapeutics, Inc. - **CIK**: 1517022 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AKBA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 180 THIRD AVENUE, WALTHAM, MA, 02451 - **Phone**: 617-871-2098 - **Shares outstanding**: 277,106,245 as of 2026-07-31 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000071/akba-20261007.htm) filed 2026-10-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/akba-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/akba-20260630.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/akba-20260617.htm) filed 2026-06-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/akba-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000034/akba-20260428.htm) filed 2026-04-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001517022), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Akebia Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AKBA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Akebia Therapeutics, Inc. - **Ticker**: AKBA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00972D1054 - **Other listed symbols**: GETTEX:AX9; LS:A1XF0S; LSX:A1XF0S - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AKBA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/akebia-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Akebia Therapeutics (AKBA) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/akebia-therapeutics/